Erratum: Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation? (British Journal of Pharmacology (2006) 149, (269-276) DOI: 10.1038/sj.bjp.0706846);Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation?

British Journal of Pharmacology

Volumn 149, Issue 3, 2006, Pages 269-276

  Baker, K E ^a,b   Wood, L M ^a,c   Whittaker, M ^a,d   Curtis, M J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b SIMBEC RESEARCH LTD   (United Kingdom)

^c Vernalis PLC   (United Kingdom)

^d EVOTEC UK LTD   (United Kingdom)

Author keywords

Antiarrhythmic; Heart; Myocardial ischaemia; Nupafant; Platelet activating factor; Ventricular fibrillation

Indexed keywords

ANTIARRHYTHMIC AGENT; NUPAFANT; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SELECTIVITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; INCIDENCE; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RAT; RAT STRAIN; VASODILATATION;

EID: 33749009808     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706958     Document Type: Erratum

References (43)

1. Annable CR, Mcmanus LR, Carey KR, Pinckard RN (1985). Isolation of platelet activating factor from ischaemic baboon myocardium. Fed Proc 44: 1271.
2. Arakawa H, Qian J-Y, Baatar D, Karasawa K, Asada Y, Sasaguri Y et al. (2005). Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipedemic rabbits. Circulation 111: 3302-3309.
3. Avkiran M, Curtis MJ (1991). Independent dual perfusion of left and right coronary arteries in isolated rat hearts. Am J Physiol 261: H2082-H2090.
4. Baker KE, Curtis MJ (1999). Protection against ventricular fibrillation by the PAF antagonist, BN-50739, involves an ischaemia-selective mechanism. J Cardiovasc Pharmacol 34: 394-401.
5. + reveals that ischaemic arrhythmias are caused by independent effects of endogenous 'mediators' facilitated by interactions, and moderated by paradoxical antagonism. Br J Pharmacol 142: 352-366.
6. Braquet P, Touqui L, Shen TY, Vargaftig BB (1987). Perspectives in platelet activating factor research. Pharm Rev 39: 97-145.
7. Chao W, Olson MS (1993). Platelet activating factor: receptors and signal transduction. Biochem J 292: 617-629.
8. Clements-Jewery H, Curtis MJ (2003). Biochemical mediators of ventricular arrhythmias in ischaemic heart disease. In: MK Pugsley (ed) Cardiac Drug Development Guide. The Humana Press Inc: Totowa, NJ, USA, pp. 203-226.
9. Clements-Jewery H, Hearse DJ, Curtis MJ (2002). The isolated blood-perfused rat heart: an inappropriate model for the study of ischaemia-induced ventricular fibrillation. Br J Pharmacol 137: 1089-1099.
10. Clements-Jewery H, Hearse DJ, Curtis MJ (2005). Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic drug development and safety pharmacology evaluation. Br J Pharmacol 145: 551-564.
11. Clements-Jewery H, Kanaganayagam GS, Kabra R, Curtis MJ (2006). Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts. Br J Pharmacol 147: 468-475.
12. Curtis MJ (1991). The rabbit dual coronary perfusion model: a new method for assessing the pathological relevance of individual products of ischaemia and reperfusion: role of potassium in arrhythmogenesis. Cardiovasc Res 25: 1010-1022.
13. Curtis MJ (1998). Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation. Cardiovasc Res 39: 194-215.
14. Curtis MJ, Baczko I, Baker KE (1997). The ECG in man and laboratory animals: recording methods, analysis and interpretation. In Walker MJA, Pugsley MK, (eds). Methods in Cardiac Electrophysiology. CRC Press: Basel. 133-158.
15. Curtis MJ, Hearse DJ (1989a). Ischaemia induced and reperfusion induced arrhythmias differ in their sensitivity to potassium: implications for mechanism of initiation and maintenance of ventricular fibrillation. J Mol Cell Cardiol 21: 21-40.
16. Curtis MJ, Hearse DJ (1989b). Reperfusion induced arrhythmias are critically dependent upon occluded zone size: relevance to the mechanism of arrhythmogenesis. J Mol Cell Cardiol 21: 625-637.
17. Curtis MJ, Pugsley MK, Walker MJA (1993). Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease. Cardiovasc Res 27: 703-719.
18. Farkas A, Curtis MJ (2003). Does QT widening in the Langendorff-perfused rat heart represent the effect of repolarization delay or conduction slowing? J Cardiovasc Pharmacol 42: 612-621.
19. Farkas A, Qureshi A, Curtis MJ (1999). Inadequate ischaemia-selectivity limits the antiarrhythmic efficacy of mibefradil during regional ischaemia and reperfusion in the rat isolated perfused heart. Br J Pharmacol 128: 41-50.
20. Flores NA, Sheridan DJ (1990). Electrophysiological and arrhythmogenic effects of PAF during normal perfusion, myocardial ischaemia and reperfusion in the guinea pig. Br J Pharmacol 101: 734-738.
21. Hwang SB (1990). Specific receptors of platelet activating factor, receptor heterogenicity and signal transduction mechanisms. J Lipid Med 2: 123-158.
22. Izumi T, Shimizu T (1995). Platelet activating receptor: gene expression and signal transduction. Biochim et Biophys Acta 1259: 317-333.
23. Jantan I, Pisar M, Mohd H, Sirat M, Basar N, Jamil S et al (2004). Inhibitory effects of compounds from zingiberaceae species on platelet activating factor receptor binding. Phytotherapy Res 18: 1005-1007.
24. Koller M, Hilger RA, Konig W (1996). Effect of PAF receptor antagonist SM-12502 on human platelets. Inflammation 20: 71-85.
25. Koltai M, TosakiI A, Hosford D, Esanu A, Braquet P (1991). Effect of BN-50739, a new platelet-activating-factor antagonist, on ischemia induced ventricular arrhythmias in isolated working rat hearts. Cardiovasc Res 25: 391-397.
26. Mueller HW, Haught CA, McNatt JM (1995). Measurement of platelet activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease. Circ Res 77: 54-63.
27. Pabla R, Curtis MJ (1996). Effect of endogenous nitric oxide on cardiac systolic and diastolic function during ischaemia and reperfusion in the rat isolated perfused heart. J Mol Cell Cardiol 28: 2111-2121.
28. Piper PJ, Stewart AG (1986). Coronary vasoconstriction in the rat, isolated perfused heart induced by PAF is mediated by LTC4. Br J Pharmacol 88: 595-605.
29. Pugsley MK (2002). Antiarrhythmic drug development: historical review and future perspectives. Drug Dev Res 55: 3-16.
30. Quistad GB, Fisher KJ, Oweb SC, Klintenberg R, Casida JE (2005). Platelet-activating factor acetylhydrolase: selective inhibition by potent n-alkyl methylphosphonofluoridates. Toxicol Appl Pharmacol 205: 149-156.
31. 1 blockade, a new antiarrhythmic mechanism? Effect of RP58866 on ventricular arrhythmias in rat, rabbit and primate. Circulation 87: 1979-1989.
32. Rees SA, Curtis MJ (1995). Further investigation into the mechanism of antifibrillatory action of the specific IK1 blocker, RP58866, assessed using the rat dual coronary perfusion model. J Mol Cell Cardiol 27: 2579-2606.
33. Rees SA, Curtis MJ (1996). Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias? Pharmacol Ther 69: 199-217.
34. Ridley PH, Yacoub MH, Curtis MJ (1992). A Modified model of global ischaemia: application to the study of syncytial mechanisms of arrhythmogenesis. Cardiovasc Res 26: 313-323.
35. Robertson DA, Genovese A, Levi R (1987). negative inotropic effect of platelet activating factor on human myocardium: a pharmacological study. J Pharmacol Exp Therapeut 243: 834-839.
36. Rosen MR (1995). Cardiac arrhythmias and anti-arrhythmic drugs: recent advances in our understanding of mechanisms. J Cardiovasc Electrophysiol 6: 868-879.
37. Tsuchihashi K, Curtis MJ (1991). Influence of tedisamil on the initiation and maintenance of ventricular fibrillation: chemical defibrillation by Ito blockade. J Cardiovasc Pharmacol 18: 455-456.
38. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF et al. (1996). Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348: 7-12.
39. Walker MJA, Curtis MJ, Hearse DJ, Campbell RWF, Janse MJ, Yellon DM et al. (1988). The Lambeth conventions: guidelines for the study of arrhythmias in ischaemia, infarction, and reperfusion. Cardiovasc Res 22: 447-455.
40. Whittaker M, Beauchamp CL, Bowles KS, Cackett MS, Christodoulou W, Galloway A et al. (1992). BB-823, a PAF receptor antagonist with picomolar activity. Pharmacol Commun 1: 251-257.
41. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M et al. (2005). Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111: 980-987.
42. Yamanaka S, Miura K, Yukimura T, Okumura M, Yamamoto K (1992). Putative mechanism of hypotensive action of platelet activating factor in dogs. Circ Res 70: 893-900.
43. Zheng ZJ, Croft JB, Giles WH, Mensah GA (2001). Sudden cardiac death in the United States, 1989 to 1998. Circulation 104: 2158-2163.